Lycia Therapeutics

Lycia Therapeutics is a South San Francisco, California biotechnology company developing a new class of targeted protein degradation medicines built on its proprietary lysosomal targeting chimera (LYTAC) platform, which originated in the Stanford University laboratory of Nobel laureate Carolyn Bertozzi, Ph.D. LYTAC molecules bind a disease-driving extracellular protein and shuttle it into the cell for destruction by the lysosome, allowing Lycia to pursue circulating and membrane-bound proteins that conventional small molecules and antibodies have been unable to drug. The company is led by President and Chief Executive Officer Aetna Wun Trombley, Ph.D., is backed by Versant Ventures, Redmile Group, Venrock, RTW and Blue Owl among others, and has partnered with Eli Lilly and Company to discover and develop LYTAC degraders. Lycia is a privately held, research-stage therapeutics company; it publishes no public developer program, API, or machine-readable API artifacts.

Lycia Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Therapeutics, Drug Discovery, and Protein Degradation.

Lycia Therapeutics’ developer surface includes engineering blog and 16 more developer resources.

🌐 Visit website 📡 Source on GitHub

10.3/100 minimal ▬ flat Agent 0/100 human only saas Full breakdown ↓
scored 2026-09-08 · rubric v0.20.0

0 APIs

Company Biotechnology Therapeutics Drug Discovery Protein Degradation Life Sciences Healthcare Pharmaceuticals

Kin Score

Kin Score How this is scored →
scored 2026-09-08 · rubric v0.20.0

Composite quality — 10.3/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.4 / 17

Access Clarity 3.6 / 17

Operational Transparency 0.0 / 11

Contract Governance 0.0 / 10

Discoverability 4.9 / 9

Regulatory Posture 2.6 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

Documented Reversibility 0 / 6

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Delegated User Identity 0 / 6

Protected Resource Metadata 0 / 5

Registration Without a Human 0 / 6

Agentic Commerce Well-Known Document 0 / 5

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero: never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and several others — scorable at all.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. Every facet and dimension name above is a link: it opens that measurement's own page — what it means, the exact checks that feed it, how the whole catalog distributes on it, and the providers at the top of it. This rating is computed from github.com/api-evangelist/lycia-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Submit an artifact on GitHub — free → Manage your own listing — the Influence plan, $499/mo →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Lycia Therapeutics Domain Security

TLSv1.3

SECURITY

Resources

Agent Surfaces 2

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt

LLMsTxt

WellKnownProbe

WellKnownProbe

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Contact

Contact

Commercial 2

Pricing, plans, and the legal terms of use

TermsOfService

TermsOfService

PrivacyPolicy

PrivacyPolicy

Company 8

The organization behind the API

Website

About

Blog

BlogRSS

Careers

Investors

Partnering

LinkedIn

Scroll for all 8

Other 3

Properties that don't map to a standard resource type

Team

Team

Technology

Technology

StockMarketplace

StockMarketplace

Source (apis.yml)

aid: lycia-therapeutics
deliveryModel:
  model: saas
  open_source: false
  commercial: true
  callable_host: false
  label: Hosted service · you call their endpoint
  confidence: medium
  source:
  - pricing
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source:
  - security
  generated: '2026-09-02'
  method: derived
image: https://lyciatx.com/wp-content/uploads/2024/10/lycia-logo.png
name: Lycia Therapeutics
description: Lycia Therapeutics is a South San Francisco, California biotechnology company developing a new class of targeted
  protein degradation medicines built on its proprietary lysosomal targeting chimera (LYTAC) platform, which originated in
  the Stanford University laboratory of Nobel laureate Carolyn Bertozzi, Ph.D. LYTAC molecules bind a disease-driving extracellular
  protein and shuttle it into the cell for destruction by the lysosome, allowing Lycia to pursue circulating and membrane-bound
  proteins that conventional small molecules and antibodies have been unable to drug. The company is led by President and
  Chief Executive Officer Aetna Wun Trombley, Ph.D., is backed by Versant Ventures, Redmile Group, Venrock, RTW and Blue Owl
  among others, and has partnered with Eli Lilly and Company to discover and develop LYTAC degraders. Lycia is a privately
  held, research-stage therapeutics company; it publishes no public developer program, API, or machine-readable API artifacts.
url: https://raw.githubusercontent.com/api-evangelist/lycia-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.23'
created: '2026-08-04'
modified: '2026-08-04'
tags:
- Company
- Biotechnology
- Therapeutics
- Drug Discovery
- Protein Degradation
- Life Sciences
- Healthcare
- Pharmaceuticals
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/lycia-therapeutics-domain-security.yml
- type: LLMsTxt
  url: llms/lycia-therapeutics-llms.txt
- type: WellKnownProbe
  url: well-known/lycia-therapeutics-well-known.yml
- type: Website
  url: https://lyciatx.com/
- type: About
  url: https://lyciatx.com/about/overview/
- type: Blog
  url: https://lyciatx.com/news/
- type: BlogRSS
  url: https://lyciatx.com/feed/
- type: Contact
  url: https://lyciatx.com/contact/
- type: TermsOfService
  url: https://lyciatx.com/terms-of-use/
- type: PrivacyPolicy
  url: https://lyciatx.com/privacy-policy/
- type: Careers
  url: https://lyciatx.com/careers/
- type: Investors
  url: https://lyciatx.com/about/investors/
- type: Team
  url: https://lyciatx.com/about/team/
- type: Technology
  url: https://lyciatx.com/technology/lytac-platform/
- type: Partnering
  url: https://lyciatx.com/about/partnering/
- type: LinkedIn
  url: https://www.linkedin.com/company/lycia-therapeutics
- type: StockMarketplace
  url: https://forgeglobal.com/lycia-therapeutics_stock/
x-enrichment:
  date: '2026-08-04'
  status: minimal
  artifacts_added: 3
  pass: local-v1

Work with this as data

Every provider here is available over the APIs.io API and to AI agents over MCP.

MCP server

One button, every client — Claude, Cursor, VS Code and the rest.

https://apis.io/mcp

Tools for providers

9 MCP tools reach this

find_providersBrowse and filter every provider in the catalog.
get_provider_artifactsEvery artifact this provider publishes, grouped by type.
get_provider_operationsEvery operation across all of their OpenAPIs — one call instead of parsing every spec.
get_provider_toolsEvery MCP tool they ship, with the operation each wraps.
get_provider_evidenceHow each part of their score was established. Free — the basis for a claim should not sit behind it.
get_provider_ratingPRO — composite, band, trend and facet scores.
apis_io_searchSTART HERE — APIs, providers and tags for one query, each with its total.
resolveTurn a domain, URL or GitHub org into the provider it belongs to.
find_cohortsEvery scored population of providers in the catalog.

All 92 tools →

Call it yourself

curl for this page

This provider

curl "https://apis.io/api/v1/providers/lycia-therapeutics"

All providers

curl "https://apis.io/api/v1/providers?limit=25"

Every operation they expose

curl "https://apis.io/api/v1/providers/lycia-therapeutics/operations?limit=25"

How their score was established

curl "https://apis.io/api/v1/providers/lycia-therapeutics/evidence"

Discovery needs no key. Ratings and market analysis are Pro.

Get an API key

Free tier, no form to fill in. Signing in shares your email address with us — we store it to create your key and to recognise you if you sign in with another provider. See our Privacy Policy and Terms.

GitHub Google LinkedIn

A second provider on the same verified email joins the account you already have.